Results 81 to 90 of about 3,094,165 (247)

The evaluation of arterial stiffness of essential hypertension and white coat hypertension in children: a case-control study

, 2018
Background: The aim of this study was to determine and compare cardiovascular risks by assessing arterial stiffness in children with essential hypertension and white coat hypertension.
Tokgoz, Semiha, Celik, BÜLENT, Tokgoz, Yavuz, Bulut, Yasin, Yilmaz, Dilek   +4 more
core   +2 more sources

Hipertensión y efecto de bata blanca. The high blood pressure and the white coat effect. [PDF]

Revista Cubana de Cardiología y Cirugía Cardiovascular, 2010
La hipertensión de bata blanca (HTABB) es aquella en que la presión arterial en el consultorio o en el hospital, es mayor que fuera de ellos. Es una variable discreta (todo o nada), que tiene el riesgo de que se catalogue a una persona normal como ...
David García Barreto, Ernesto Groning Roque, Raymid García Fernández, Alberto Hernández Cañero   +3 more
doaj  

Prevalence and Clinical Characteristics of Refractory Hypertension

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundWe aimed to estimate the prevalence of refractory hypertension (RfH) and to determine the clinical differences between these patients and resistant hypertensives (RH).
Pedro Armario, David A. Calhoun, Anna Oliveras, Pedro Blanch, Ernest Vinyoles, Jose R. Banegas, Manuel Gorostidi, Julián Segura, Luis M. Ruilope, Tanja Dudenbostel, Alejandro de la Sierra   +10 more
doaj   +1 more source

White coat hypertension : to treat or not to treat?

, 2016
Definition of white coat hypertension (WCH) traditionally relies on elevated office blood pressure (BP) during repeated visits concomitant with normal out-of-office BP values, as assessed by home and/or 24-h ambulatory BP monitoring measurements ...
C. Cuspidi, C. Sala, G. Grassi, G. Mancia   +3 more
core   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz, Seza Ozen, Hacer Neslihan Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet Emin Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet Orhan Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Circulating homocysteine levels in sustained and white coat hypertension

, 2003
Although white coat hypertension has been widely studied in the last years, its risk profile is not yet completely clear. The aim of this study was to evaluate circulating homocysteine levels, an emerging cardiovascular risk factor, in subjects with ...
BUCCI A, LATTANZIO FM, PIERDOMENICO, Sante Donato, LAPENNA, Domenico, TALONE L, CUCCURULLO, Franco, MEZZETTI, Andrea   +6 more
core  

Endothelium and angiogenesis in white coat hypertension

, 2004
Hypertensive patients are at particular risk of cardiovascular complications, possibly related to endothelial damage or dysfunction, or to abnormal angiogenesis.
Simsek, G, UZUN, H, KARTER, Y, ERTÜRK, N, ÇURGUNLU, A, Karter, Yesari, YÜCEL, Rauf, ERDİNE, S, Uzun, Hafize, ÇURGUNLU, Aslı, YÜCEL, R, AYDIN, SİNAN, Aydin, S, KUTLU, Akif Emre, ARAT, A, ERTÜRK, Nurten, ÖZTÜRK, E, VEHİD, S, ARAT, Asiye, Vehid, Suphi, KUTLU, AYŞE   +20 more
core   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Urinary markers of renal damage in hypertensive children diagnosed with ambulatory blood pressure monitoring

The Turkish Journal of Pediatrics, 2014
Primary hypertension is the most important risk factor for chronic kidney disease in adulthood. However, the role of hypertension in kidney damage in childhood is not known exactly.
İlknur Girişgen, Ferah Sönmez, Ciğdem Yenisey, İmran Kurt-Omurlu   +3 more
doaj  

Automated Office Blood Pressure Measurements in Waiting Room or Isolated Room for Diagnosis and Phenotyping of Hypertension

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Automatic office blood pressure measurement (AOBPM) in the waiting room could improve the performance of diagnosing hypertension without requiring an isolated room to carry out exploration.
Marisol Sánchez Bacaicoa, Sergio Rico, Alejandra Gullón, Jacinto Fernandez Pardo, Juan Villa, Eva Nadiejda, Roberto Robles, Jose M. del Aguila, Pedro Cunha, Valentina Vassilenko, Enrique Rodilla, Juan F. Sánchez Muñoz‐Torrero   +11 more
doaj   +1 more source